How much PDL-1 expression is necessary for a clinically meaningful response to PD-1 or PDL-1 blockade is not well quantified and varies across different cancer types (from ≥1% to ≥50% positive PDL-1 cells), and even different checkpoint inhibitors. This evidence concerns the gene CD274 and cancer.